A comparison of the platelet index, neutrophil-lymphocyteand platelet-lymphocyte ratios of patients withdifferentiated thyroid cancer and nodular hyperplasia

Aim: In our study, it was aimed to determine the usability of the inexpensive, fast and easily accessible platelet index, NLR (Neutrophil to Lymphocyte ratio) and PLR (Platelet to Lymphocyte ratio) as predictive values in patients with differentiated thyroid cancer and nodular hyperplasia. Materials and Methods: The data of 454 patients operated due to differentiated thyroid cancers and nodular hyperplasia at our clinic between 2010 and 2020 and a control group consisting of 120 healthy individuals were retrospectively examined. The data of the patients and the control group were statistically analyzed. Results: The study included a total of 574 participants including 314 patients who received differentiated thyroid cancer surgery, 140 patients who received surgery due to thyroid nodular hyperplasia and a control group consisting of 120 healthy individuals. There was no significant difference among the groups in terms of age. There was a dominance of the female sex among the groups, but the difference was insignificant. There was no significant difference among the groups in terms of their MPV, PLR or NLR values. However, the PDW (Platelet Distribution Width) values were significantly higher among the differentiated thyroid cancer patients.Conclusion: In our study, we observed that the MPV, PLR and NLR values varied, but the differences were not statistically significant. The PDW values were significantly high. Considering the current literature, we concluded that, among the existing parameters, NLR is a more reliable constant value at the stage of diagnosis.

PDF

___

1. Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1- 133.
2. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388:2783-95.
3. Smith-Bindman R, Lebda P, Feldstein VA, et al. Risk of thyroid cancer based on thyroid ultrasound imaging characteristics: results of a population-based study. JAMA Intern Med 2013;173:1788-96.
4. Sosa JA, Hanna JW, Robinson KA, et al. Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. Surgery 2013;154:1420-7.
5. Durante C, Costante G, Lucisano G, et al. The natural history of benign thyroid nodules. JAMA 2015;313:926-5.
6. Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 2002;87:1941-6.
7. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
8. Carling T, Udelsman R. Thyroid cancer. Annu Rev Med 2014;65:125-37.
9. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014;140:317-22.
10. Mascarella MA, Mannard E, Silva SD, et al. Neutrophilto-lymphocyte ratio in head and neck cancer prognosis: A systematic review and meta-analysis. Head Neck 2018;40:1091-1100.
11. Akenaka Y, Oya R, Kitamiura T, et al. Prognostic role of neutrophil-to-lymphocyte ratio in head and neck cancer: A meta-analysis. Head Neck 2018;40:647- 655.
12. Tham T, Bardash Y, Herman SW, et al. Neutrophil-tolymphocyte ratio as a prognostic indicator in head and neck cancer: A systematic review and meta-analysis. Head Neck 2018;40:2546-57.
13. Wong R, Farrell SG, Grossmann M. Thyroid nodules: diagnosis and management. Med J Aust 2018;209:92- 8.
14. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19:1423-37.
15. Cools-Lartigue J, Spicer J, McDonald B, et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis [published online ahead of print, 2013 Jul . J Clin Invest 2013;123:3446- 58.
16. Park J, Wysocki RW, Amoozgar Z, et al. Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci Transl Med 2016;8:361ra138.
17. Dumitru CA, Moses K, Trellakis S, et al. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother 2012;61:1155-67.
18. Yamanaka T, Matsumoto S, Teramukai S,et al. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007;73:215-20.
19. Liu CL, Lee JJ, Liu TP, et al. Blood neutrophil-tolymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer. J Surg Oncol 2013;107:493-7.
20. Wee JL, Greenwood DL, Han X, et al. Inflammatory cytokines IL-6 and TNF-α regulate lymphocyte trafficking through the local lymph node. Vet Immunol Immunopathol 2011;144:95-103.
21. Lee F, Yang PS, Chien MN,et al. An Increased Neutrophil-to-Lymphocyte Ratio Predicts Incomplete Response to Therapy in Differentiated Thyroid Cancer. Int J Med Sci. 2018;15:1757-63.
22. Gong W, Yang S, Yang X, Guo F. Blood preoperative neutrophil-to-lymphocyte ratio is correlated with TNM stage in patients with papillary thyroid cancer. Clinics (Sao Paulo) 2016;71:311-4.
23. Ari A, Gunver F. Comparison of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with thyroiditis and papillary tumors. J Int Med Res 2019;47:2077-83.
24. Yaylaci S, Tosun O, Sahin O, et al. Lack of Variation in Inflammatory Hematological Parameters between Benign Nodular Goiter and Papillary Thyroid Cancer. Asian Pac J Cancer Prev 2016;17:2321-3.
25. Machairas N, Kostakis ID, Prodromidou A, et al. Trends in white blood cell and platelet indices in a comparison of patients with papillary thyroid carcinoma and multinodular goiter do not permit differentiation between the conditions. Endocr Res 2017;42:311-7.
26. Baldane S, Ipekci SH, Sozen M, et al. Mean platelet volume could be a possible biomarker for papillary thyroid carcinomas. Asian Pac J Cancer Prev 2015;16:2671-4.
27. Dincel O, Bayraktar C. Evaluation of platelet indices as a useful marker in papillary thyroid carcinoma. Bratisl Lek Listy 2017;118:153-5.
28. Tuncel T, Ozgun A, Emirzeoglu L, et al. Mean platelet volume as a prognostic marker in metastatic colorectal cancer patients treated with bevacizumabcombined chemotherapy. Asian Pac J Cancer Prev 2014;15:6421-3.
29. Yildiz S, Eker E, Ozturk M, Alay M. A comparison of haemogram parameters of patients with thyroid papillary cancer and nodular goiter in Van, Turkey. J Pak Med Assoc 2019;69:1642-6.
30. Yu YJ, Li N, Yun ZY, et al. Preoperative mean platelet volume and platelet distribution associated with thyroid cancer. Neoplasma 2017;64:594-8.
31. Alsweedan SA, Al-Shurman A, Mahmoud AS. Diagnostic value of platelet indices in children with leukemia. J Pediatr Hematol Oncol 2008;30:953-5.
32. Kutluturk F, Gul SS, Sahin S, et al. Comparison of mean platelet volume, platelet count, neutrophil/ lymphocyte ratio and platelet/lymphocyte ratio in the euthyroid, overt hypothyroid and subclinical hyperthyroid phases of papillary thyroid carcinoma. Endocr Metab Immune Disord Drug Targets 2019;19:859-65.